Kiniksa Pharmaceuticals International, plc

NasdaqGS:KNSA Voorraadrapport

Marktkapitalisatie: US$1.5b

Kiniksa Pharmaceuticals International Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Kiniksa Pharmaceuticals International is de winst gegroeid met een gemiddeld jaarlijks percentage van 45.9%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.1%. De inkomsten zijn gegroeid met een gemiddelde van 65.2% per jaar.

Belangrijke informatie

45.9%

Groei van de winst

48.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei65.2%
Rendement op eigen vermogen-2.1%
Nettomarge-2.4%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

Oct 07

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 07
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Jul 24

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Jun 19
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Apr 25
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Apr 24

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Opbrengsten en kosten

Hoe Kiniksa Pharmaceuticals International geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:KNSA Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 24384-916496
30 Jun 24339-1015288
31 Mar 24302913987
31 Dec 232701412976
30 Sep 23249-712070
30 Jun 2328123111070
31 Mar 2323619610560
31 Dec 222201839865
30 Sep 221771439379
30 Jun 2290-1129081
31 Mar 2271-1348891
31 Dec 2139-1588699
30 Sep 2120-17579109
30 Jun 218-18970121
31 Mar 210-18457120
31 Dec 200-16145112
30 Sep 200-1403899
30 Jun 200-1233589
31 Mar 200-1223597
31 Dec 190-16235135
30 Sep 190-17335147
30 Jun 190-17031146
31 Mar 190-15327133
31 Dec 180-1032287
30 Sep 180-931680
30 Jun 180-851374
31 Mar 180-761165
31 Dec 170-65956

Kwaliteitswinsten: KNSA is momenteel verliesgevend.

Groeiende winstmarge: KNSA is momenteel verliesgevend.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: KNSA is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 45.9% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van KNSA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: KNSA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).


Rendement op eigen vermogen

Hoge ROE: KNSA heeft een negatief Return on Equity ( -2.08% ), omdat het momenteel verliesgevend is.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden